Jailal N. Ablack

Jailal N. Ablack

Auto-generated profile, based on publicly available information

Jailal N. Ablack

Department of Medicine, University of California San Diego School of Medicine , La Jolla, CA 92093

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2011 in Small
Verified
Journal Article
Open access
PDF file
NSNicole Steinmetz
Nicole Steinmetz
AAAmber L. Ablack
Amber L. Ablack
JHJennifer L. Hickey
Jennifer L. Hickey
JAJailal Ablack
Jailal Ablack
BMBhavik Manocha
Bhavik Manocha
JLJohn D. Lewis
John D. Lewis
Multivalent nanoparticles have several key advantages in terms of solubility, binding avidity, and uptake, making them particularly well suited to molecular imaging applications. Herein is reported the stepwise synthesis and characterization of NIR viral nanoparticles targeted to gastrin‐releasing peptide receptors that are over‐expressed in human prostate cancers. The pan‐bombesin analogue, [β‐Ala11, Phe13, Nle14]bombesin‐(7–14), is conjugated to cowpea mosaic virus particles functionalized with an NIR dye (Alexa Fluor 647) and polyethylene glycol (PEG) using the copper(I)‐catalyzed azide‐alkyne cycloaddition reaction. Targeting and uptake in human PC‐3 prostate cells is demonstrated in vitro. Tumor homing is observed using human prostate tumor xenografts on the chicken chorioallantoic membrane model using intravital imaging. Further development of this viral nanoparticle platform may open the door to potential clinical noninvasive molecular imaging strategies.

3 September 2020 in Blood
Verified
Journal Article
Open access
PDF file
FLFrederic Lagarrigue
Frederic Lagarrigue
DPDavid S. Paul
David S. Paul
AGAlexandre R. Gingras
Alexandre R. Gingras
AVAndrew J. Valadez
Andrew J. Valadez
HSHao Sun
Hao Sun
MGMark H. Ginsberg
Mark H. Ginsberg
Ras-related protein 1 (Rap1) is a major convergence point of the platelet-signaling pathways that result in talin-1 binding to the integrin β cytoplasmic domain and consequent integrin activation, platelet aggregation, and effective hemostasis. The nature of the connection between Rap1 and talin-1 in integrin activation is an important remaining gap in our understanding of this process. Previous work identified a low-affinity Rap1-binding site in the talin-1 F0 domain that makes a small contribution to integrin activation in platelets. We recently identified an additional Rap1-binding site in the talin-1 F1 domain that makes a greater contribution than F0 in model systems. Here we generated mice bearing point mutations, which block Rap1 binding without affecting talin-1 expression, in either the talin-1 F1 domain (R118E) alone, which were viable, or in both the F0 and F1 domains (R35E,R118E), which were embryonic lethal. Loss of the Rap1–talin-1 F1 interaction in platelets markedly decreases talin-1–mediated activation of platelet β1- and β3-integrins. Integrin activation and platelet aggregation in mice whose platelets express only talin-1(R35E, R118E) are even more impaired, resembling the defect seen in platelets lacking both Rap1a and Rap1b. Although Rap1 is important in thrombopoiesis, platelet secretion, and surface exposure of phosphatidylserine, loss of the Rap1–talin-1 interaction in talin-1(R35E, R118E) platelets had little effect on these processes. These findings show that talin-1 is the principal direct effector of Rap1 GTPases that regulates platelet integrin activation in hemostasis.

15 June 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JKJane E Klann
Jane E Klann
SKStephanie H. Kim
Stephanie H. Kim
KRKelly A Remedios
Kelly A Remedios
ZHZhaoren He
Zhaoren He
PMPatrick J. Metz
Patrick J. Metz
JCJohn T. Chang
John T. Chang
Maintenance of the regulatory T (Treg) cell pool is essential for peripheral tolerance and prevention of autoimmunity. Integrins, heterodimeric transmembrane proteins consisting of α and β subunits that mediate cell-to-cell and cell-to-extracellular matrix interactions, play an important role in facilitating Treg cell contact–mediated suppression. In this article, we show that integrin activation plays an essential, previously unappreciated role in maintaining murine Treg cell function. Treg cell–specific loss of talin, a β integrin–binding protein, or expression of talin(L325R), a mutant that selectively abrogates integrin activation, resulted in lethal systemic autoimmunity. This dysfunction could be attributed, in part, to a global dysregulation of the Treg cell transcriptome. Activation of integrin α4β1 led to increased suppressive capacity of the Treg cell pool, suggesting that modulating integrin activation on Treg cells may be a useful therapeutic strategy for autoimmune and inflammatory disorders. Taken together, these results reveal a critical role for integrin-mediated signals in controlling peripheral tolerance by virtue of maintaining Treg cell function.

1 January 2015 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
JAJailal N. G. Ablack
Jailal N. G. Ablack
JCJoseph M. Cantor
Joseph M. Cantor
PMPatrick J. Metz
Patrick J. Metz
JCJohn T. Chang
John T. Chang
MGMark H. Ginsberg
Mark H. Ginsberg
CD98 heavy chain (SLC3A2) facilitates lymphocyte clonal expansion that enables adaptive immunity; however, increased expression of CD98 is also a feature of both lymphomas and leukemias and represents a potential therapeutic target in these diseases. CD98 is transcriptionally regulated and ectopic expression of the membrane-associated RING-CH (MARCH) E3 ubiquitin ligases MARCH1 or MARCH8 leads to ubiquitylation and lysosomal degradation of CD98. Here, we examined the potential role of ubiquitylation in regulating CD98 expression and cell proliferation. We report that blocking ubiquitylation by use of a catalytically inactive MARCH or by creating a ubiquitylation-resistant CD98 mutant, prevents MARCH-induced CD98 downregulation in HeLa cells. March1-null T cells display increased CD98 expression. Similarly, T cells expressing ubiquitylation-resistant CD98 manifest increased proliferation in vitro and clonal expansion in vivo. Thus, ubiquitylation and the resulting downregulation of CD98 can limit cell proliferation and clonal expansion.

19 October 2020 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
JAJailal N. Ablack
Jailal N. Ablack
JOJesus Ortiz
Jesus Ortiz
JBJeevisha Bajaj
Jeevisha Bajaj
KTKathleen Trinh
Kathleen Trinh
FLFrederic Lagarrigue
Frederic Lagarrigue
MGMark H. Ginsberg
Mark H. Ginsberg
CD98, which is required for the rapid proliferation of both normal and cancer cells, and MET, the hepatocyte growth factor receptor, are potential targets for therapeutic antitumor Abs. In this study, we report that the antiproliferative activity of a prototype anti-CD98 Ab, UM7F8, is due to Ab-induced membrane-associated ring CH (MARCH) E3 ubiquitin ligase-mediated ubiquitination and downregulation of cell surface CD98. MARCH1-mediated ubiquitination of CD98 is required for UM7F8’s capacity to reduce CD98 surface expression and its capacity to inhibit the proliferation of murine T cells. Similarly, CD98 ubiquitination is required for UM7F8’s capacity to block the colony-forming ability of murine leukemia–initiating cells. To test the potential generality of the paradigm that MARCH E3 ligases can mediate the antiproliferative response to antitumor Abs, we examined the potential effects of MARCH proteins on responses to emibetuzumab, an anti-MET Ab currently in clinical trials for various cancers. We report that MET surface expression is reduced by MARCH1, 4, or 8-mediated ubiquitination and that emibetuzumab-induced MET ubiquitination contributes to its capacity to downregulate MET and inhibit human tumor cell proliferation. Thus, MARCH E3 ligases can act as cofactors for antitumor Abs that target cell surface proteins, suggesting that the MARCH protein repertoire of cells is a determinant of their response to such Abs.